NCT05158972

Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 924 (actual)
• Sponsor: Mylan Inc. · Industry
• Sex: All
• Age: 6 Years
• Healthy volunteers: Not accepted

Summary

Gathering knowledge on the use of Dymista® in Asian patients who receive Dymista® for the first time in routine clinical practice

Detailed description

A) Primary objective: Gathering knowledge on the use of Dymista® in Asian patients who receive Dymista® for the first time in routine clinical practice; Patient's demographic; Anamnestic background including: * allergic and other comorbidities * allergic conjunctivitis * polysensitization * current symptoms * previous treatments of allergic rhinitis * usage of current asthma reliever medication * family history of allergy B) Secondary Objective: * Response to therapy with Dymista® nasal spray in routine clinical practice. * Quality of sleep (by VAS) * Troublesomeness in daily activities (by VAS) * Patient's assessment about the regular use of Dymista® * Patients opinion about continuation of Dymista® treatment after end of the observational period

Conditions

• Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	Dymista	1 spray per nostril twice daily up to four weeks

Timeline

• Start date: 2021-10-27
• Primary completion: 2023-10-24
• Completion: 2023-10-24
• First posted: 2021-12-15
• Last updated: 2023-11-13

Locations

33 sites across 4 countries: Hong Kong, Malaysia, Taiwan, Thailand